IL124676A0 - Improved concentrated injection and infusion solutions for intravenous use - Google Patents

Improved concentrated injection and infusion solutions for intravenous use

Info

Publication number
IL124676A0
IL124676A0 IL12467697A IL12467697A IL124676A0 IL 124676 A0 IL124676 A0 IL 124676A0 IL 12467697 A IL12467697 A IL 12467697A IL 12467697 A IL12467697 A IL 12467697A IL 124676 A0 IL124676 A0 IL 124676A0
Authority
IL
Israel
Prior art keywords
infusion solutions
intravenous use
concentrated injection
improved concentrated
injection
Prior art date
Application number
IL12467697A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of IL124676A0 publication Critical patent/IL124676A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0452—Solutions, e.g. for injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12467697A 1996-01-25 1997-01-27 Improved concentrated injection and infusion solutions for intravenous use IL124676A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19604095 1996-01-25
PCT/DE1997/000170 WO1997026862A2 (de) 1996-01-25 1997-01-27 Verbesserte konzentrierte injektions- und infusionslösungen für die intravasale anwendung

Publications (1)

Publication Number Publication Date
IL124676A0 true IL124676A0 (en) 1998-12-06

Family

ID=7784538

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12467697A IL124676A0 (en) 1996-01-25 1997-01-27 Improved concentrated injection and infusion solutions for intravenous use

Country Status (21)

Country Link
US (1) US6638913B1 (enExample)
EP (1) EP0876140B1 (enExample)
JP (1) JP2000505789A (enExample)
KR (1) KR100505772B1 (enExample)
CN (1) CN1209751A (enExample)
AT (1) ATE251893T1 (enExample)
AU (1) AU2150497A (enExample)
BG (1) BG62913B1 (enExample)
BR (1) BR9707081A (enExample)
CA (1) CA2244209C (enExample)
CZ (1) CZ234898A3 (enExample)
DE (2) DE59710863D1 (enExample)
DK (1) DK0876140T3 (enExample)
ES (1) ES2208884T3 (enExample)
HU (1) HUP9901355A3 (enExample)
IL (1) IL124676A0 (enExample)
NO (1) NO983438L (enExample)
PL (1) PL328199A1 (enExample)
PT (1) PT876140E (enExample)
SK (1) SK101398A3 (enExample)
WO (1) WO1997026862A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
WO1999022759A1 (en) * 1997-10-31 1999-05-14 Walter Reed Army Institute Of Research Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
EP1087934B1 (en) 1998-04-01 2004-02-25 Nortran Pharmaceuticals Inc. Aminocyclohexyl ether compounds and uses thereof
US7057053B2 (en) 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7524879B2 (en) 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
AU1344102A (en) 2000-10-12 2002-04-22 Genentech Inc Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US20020169112A1 (en) * 2001-05-08 2002-11-14 Luc Montagnier Combined treatments and methods for treatment of mycoplasma and mycoplasma-like organism infections
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
BR122018009866B8 (pt) 2003-05-02 2021-07-27 Cardiome Pharma Corp métodos para preparar compostos de éter aminocicloexílico e compostos intermediários
US7345087B2 (en) 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
WO2005113011A2 (en) 2004-04-01 2005-12-01 Cardiome Pharma Corp. Prodrugs of ion channel modulating compounds and uses thereof
WO2005097087A2 (en) 2004-04-01 2005-10-20 Cardiome Pharma Corp. Merged ion channel modulating compounds and uses thereof
EP1868598B1 (en) 2004-11-08 2014-04-23 Cardiome Pharma Corp. A new dosing regimen for ion channel modulating compounds for treating acute atrial fibrillation in a human
US20060270708A1 (en) * 2005-05-25 2006-11-30 Navinta Llc Novel process for preparation of isotonic aqueous injection of ropivacaine
EP1897535A1 (en) * 2006-08-30 2008-03-12 Dirinco AG Substitution fluid for haemofiltration
US20090239894A1 (en) * 2008-03-20 2009-09-24 Bjorn Schurad Stabilized aqueous solutions of ergoline compounds
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
US9427186B2 (en) * 2009-12-04 2016-08-30 Endomagnetics Ltd. Magnetic probe apparatus
US10634741B2 (en) * 2009-12-04 2020-04-28 Endomagnetics Ltd. Magnetic probe apparatus
KR101807894B1 (ko) 2010-03-01 2017-12-12 바이엘 헬스케어 엘엘씨 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체
CN102319258B (zh) * 2011-08-04 2012-10-31 山西诺成制药有限公司 一种5%葡萄糖置换液及其制备方法
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2014140543A1 (en) 2013-03-11 2014-09-18 Endomagnetics Ltd. Hypoosmotic solutions for lymph node detection
US9234877B2 (en) 2013-03-13 2016-01-12 Endomagnetics Ltd. Magnetic detector
US9239314B2 (en) 2013-03-13 2016-01-19 Endomagnetics Ltd. Magnetic detector
US20160279269A1 (en) * 2013-03-27 2016-09-29 Ge Healthcare As Method and reagent for preparing a diagnostic composition
WO2016193753A2 (en) 2015-06-04 2016-12-08 Endomagnetics Ltd. Marker materials and forms for magnetic marker localization (mml)
US11207412B2 (en) * 2018-04-16 2021-12-28 Merck Patent Gmbh Viscosity reduction of highly concentrated protein formulations
CN110327292A (zh) * 2019-08-11 2019-10-15 天津乾丰瑞科技有限公司 一种盐酸法舒地尔注射制剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754523A (fr) * 1969-08-06 1971-02-08 Beecham Group Ltd Vaccins
FR2435253A1 (fr) * 1978-07-04 1980-04-04 Nyegaard & Co As Procede de preparation d'une solution tamponnee d'une substance de contraste pour rayons x, et produits obtenus par ce procede
JPS58500563A (ja) * 1981-04-27 1983-04-14 バクスタ−、トラベノ−ル、ラボラトリ−ズ、インコ−ポレイテツド グルコ−ス、アミノ酸およびインシユリンを含む透析液
ATE82500T1 (de) * 1984-06-22 1992-12-15 Richard L Veech Elektrolytloesungen und deren (in vivo) verwendung.
IE60901B1 (en) * 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
GB8906130D0 (en) * 1989-03-17 1989-05-04 Nycomed As Compositions
JPH0341033A (ja) * 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
EP0437662B1 (de) 1990-01-18 1994-09-14 Cereria Amos Sgarbi S.P.A. Grablicht
GB9020091D0 (en) * 1990-09-14 1990-10-24 Nycomed As Contrast media
DE4135193C1 (enExample) * 1991-10-22 1993-03-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
IT1256248B (it) * 1992-12-24 1995-11-29 Bracco Spa Formulazioni iniettabili acquose per radiodiagnostica comprendenti miscele di composti aromatici iodurati utili come agenti opacizzanti ai raggi x
WO1995026331A1 (es) * 1994-03-25 1995-10-05 Centro Investigacion Justesa Imagen, S.A. Nuevos dimeros iodados no ionicos como agentes de contraste a los rayos x, metodo para su preparacion y composiciones farmaceuticas que los contienen
DE4446694A1 (de) * 1994-12-09 1996-06-13 Schering Ag Verwendung von Zusätzen zu Kontrastmitteln zur Verbesserung der Bildgebung

Also Published As

Publication number Publication date
CA2244209A1 (en) 1997-07-31
CN1209751A (zh) 1999-03-03
HUP9901355A2 (hu) 1999-08-30
CA2244209C (en) 2007-10-23
US6638913B1 (en) 2003-10-28
KR100505772B1 (ko) 2005-10-25
KR19990081979A (ko) 1999-11-15
EP0876140A2 (de) 1998-11-11
ATE251893T1 (de) 2003-11-15
PT876140E (pt) 2004-02-27
JP2000505789A (ja) 2000-05-16
HUP9901355A3 (en) 2000-06-28
WO1997026862A2 (de) 1997-07-31
AU2150497A (en) 1997-08-20
BG102644A (en) 1999-06-30
WO1997026862A3 (de) 1997-10-23
ES2208884T3 (es) 2004-06-16
DE59710863D1 (de) 2003-11-20
SK101398A3 (en) 1998-12-02
DE19703816A1 (de) 1997-08-07
NO983438L (no) 1998-09-18
NO983438D0 (no) 1998-07-24
BR9707081A (pt) 1999-05-25
DK0876140T3 (da) 2003-12-15
EP0876140B1 (de) 2003-10-15
CZ234898A3 (cs) 1998-11-11
PL328199A1 (en) 1999-01-18
BG62913B1 (bg) 2000-11-30

Similar Documents

Publication Publication Date Title
IL124676A0 (en) Improved concentrated injection and infusion solutions for intravenous use
MY133569A (en) Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
EP0935415A4 (en) METHOD FOR MAKING CONNECTIONS INTO A CELL
BG104812A (en) New dihydropyrimidines
SG93791A1 (en) Synthetic polynucleotides
EP0648511A3 (de) Injektionsspritze.
ZA98361B (en) Hypodermic injection system.
BG103805A (en) Trifluoromethylalkylaminotriazolopyrimidines with fungicidal effect
MY109880A (en) Substituted biphenylpyridones
DK0728148T3 (da) Forbedrede immunogene sammensætninger mod humant gastrin 17
ZA938844B (en) Injectable composition.
GB9714564D0 (en) Composition
EP0602512A3 (de) Copolymerisate des Propylens mit verringerter Weissbruchneigung.
AU1815899A (en) Method and composition to enhance the efficacy of a vaccine using chemokines
MY126562A (en) Pharmaceutical compositions based on dalfopristine and on quinupristine and their preparation
MX9602836A (es) MEZCLA QUE CONTIENE UNO O VARIOS ALFA-AMINOACIDOS Y SUS DERIVADOS, O AMBOS, Y UNO O VARIOS CICLOPENTANO- beta-AMINOACIDOS Y SUS DERIVADOS, O AMBOS.
HUP9901605A3 (en) Additive for stabilizing fuel of water content, the stabilized fuel and application thereof
EA199800819A1 (ru) Способ лечения биполярного расстройства
IL139303A0 (en) Treatment of arthritis and other similar conditions
EA199900579A1 (ru) Применение ингибиторов комт для производства лекарственного средства для профилактики сосудистых дисфункций при диабете
AU2768697A (en) Acyl urea compounds for the treatment of coccidioidomycosis in warm-blooded animals
BG101526A (en) Antiphlogistic composition for external application
MY108690A (en) Mildewproofing agent for timber
UA67243A (en) Immune modulator used in dehelminthization of dogs
MX9700388A (es) Ciclopentanopiridil-oxazolidinonas que contienen heteroatomos.